Catalog No.S1888 Synonyms: MDL 458

For research use only.

Deflazacort (MDL 458) is a glucocorticoid used as an anti-inflammatory and immunosuppressant.

Deflazacort  Chemical Structure

CAS No. 14484-47-0

Selleck's Deflazacort has been cited by 1 Publication

Purity & Quality Control

Choose Selective Glucocorticoid Receptor Inhibitors

Biological Activity

Description Deflazacort (MDL 458) is a glucocorticoid used as an anti-inflammatory and immunosuppressant.
Glucocorticoid receptor [1]
In vivo Deflazacort results in a significant and equal decrease of thymus weight, indicating a marked reduction in total immunogenic tissue in rats. [1] Deflazacort reduces thymus weight and Daily weight gain in rats. Deflazacort lowers liver IFG-I and GHR mRNA in rats. [2] Deflazacort (DFC) is a heterocyclic glucocorticoid with anti-inflammatory activity but with decreased side effects. Deflazacort and [3H]dexamethasone (DEX) similarly induce in vivo ornithine decarboxylase activity in hippocampus and liver, although body weight loss after chronic treatment is significantly less for DFC. [3] Deflazacort induces dose-dependent decreases in osteocalcin (OC) plasma production rate (PPR). Deflazacort and prednisolone increase both postabsorptive plasma glucose and plasma calcium levels in sheep, but there are no significant differences between their effects. [4] Deflazacort, especially combined with L-arginine, spares quadriceps muscle from injury-induced regeneration (myf5 expression) compared with placebo treatment, despite an increase in membrane permeability immediately after exercise. Deflazacort alone prevents the typical progressive loss of function (measured as voluntary distance run over 24 hours) that is observed 3 months later in placebo-treated mice. [5] Deflazacort causes a less significant alteration in the pattern of GH secretion and does not negatively affect the overall amount of GH secreted. [6]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 441.52


CAS No. 14484-47-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04791345 Recruiting Drug: Methylprednisone|Drug: Deflazacort|Drug: Dexamethasone Healthy Volunteers Parc de Salut Mar February 26 2021 Phase 1
NCT03783923 Terminated Drug: Deflazacort Limb-Girdle Muscular Dystrophy PTC Therapeutics October 31 2019 Phase 3
NCT03642145 Withdrawn Drug: Deflazacort Duchenne Muscular Dystrophy PTC Therapeutics October 31 2018 Phase 3
NCT02251600 Completed Drug: Deflazacort Duchenne Muscular Dystrophy PTC Therapeutics December 2014 Phase 1
NCT02286622 Completed Drug: Deflazacort Renal Impairment PTC Therapeutics December 2014 Phase 1

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Deflazacort | Deflazacort ic50 | Deflazacort price | Deflazacort cost | Deflazacort solubility dmso | Deflazacort purchase | Deflazacort manufacturer | Deflazacort research buy | Deflazacort order | Deflazacort mouse | Deflazacort chemical structure | Deflazacort mw | Deflazacort molecular weight | Deflazacort datasheet | Deflazacort supplier | Deflazacort in vitro | Deflazacort cell line | Deflazacort concentration | Deflazacort nmr